Donna E Hogge

List of Publications by Year
in descending order

135 papers	6,867 citations	66343 42 h-index	62596 80 g-index
135 all docs	135 docs citations	135 times ranked	7699 citing authors

#	Article	IF	Citations
1	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 2684-2692.	1.6	682
2	Identification of miR-145 and miR-146a as mediators of the 5qâ€“ syndrome phenotype. Nature Medicine, 2010, 16, 49-58.	30.7	588
3	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 984-997.	10.7	330
4	Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood, 2014, 123, 3239-3246.	1.4	298
5	Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood, 2003, 101, 3142-3149.	1.4	267
6	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood, 2006, 108, 88-96.	1.4	226
7	Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1187-1192.	7.1	168
8	Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice. Blood, 1999, 94, 1761-1772.	1.4	151
9	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. Blood, 1998, 92, 1910-1917.	1.4	147
10	Phase II, multicenter, randomized trial of CPXâ€351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer, 2015, 121, 234-242.	4.1	144
11	Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leukemia and Lymphoma, 2008, 49, 543-553.	1.3	138
12	Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood, 2003, 101, 4529-4538.	1.4	136
13	Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood, 2004, 103, 333-339.	1.4	130
14	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	10.7	129
15	Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood, 2002, 100, 862-868.	1.4	118
16	Wnt Inhibitor Screen Reveals Iron Dependence of Î²-Catenin Signaling in Cancers. Cancer Research, 2011, 71, 7628-7639.	0.9	115
17	Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38â^’ progenitor cells from patients with acute myeloid leukemia. Blood, 2001, 97, 3882-3889.	1.4	112
18	High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood, 2005, 106, 1473-1478.	1.4	112

#	Article	IF	Citations
19	Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood. British Journal of Haematology, 1997, 98, 1026-1036.	2.5	109
20	Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood, 2001, 97, 2286-2292.	1.4	98
21	A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Research, 2002, 62, 1730-6.	0.9	96
22	Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. American Journal of Hematology, 1983, 14, 363-369.	4.1	93
23	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology,the, 2021, 8, e481-e491.	4.6	92
24	Detection and Characterization of Primitive Malignant and Normal Progenitors in Patients With Acute Myelogenous Leukemia Using Long-Term Coculture With Supportive Feeder Layers and Cytokines. Blood, 1997, 90, 2555-2564.	1.4	87
25	MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Experimental Hematology, 2008, 36, 433-442.	0.4	87
26	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. American Journal of Hematology, 2014, 89, 363-368.	4.1	79
27	Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. British Journal of Haematology, 2005, 131, 223-230.	2.5	78
28	Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Research, 2009, 33, 271-275.	0.8	74
29	Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Experimental Hematology, 2011, 39, 741-750.	0.4	74
30	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2005, 23, 7994-8002.	1.6	62
31	Unfulfilled Promise of Endostatin in a Gene Therapy-Xenotransplant Model of Human Acute Lymphocytic Leukemia. Molecular Therapy, 2002, 5, 352-359.	8.2	58
32	A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Frontiers in Genetics, 2013, 4, 231.	2.3	57
33	Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice. Blood, 1999, 94, 1761-1772.	1.4	57
34	Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood, 2006, 108, 3530-3537.	1.4	55
35	Quantitation and characterization of human megakaryocyte colonyâ€forming cells using a standardized serumâ€free agarose assay. British Journal of Haematology, 1997, 96, 790-800.	2.5	51
36	A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia. Nature Communications, 2021, 12, 2474.	12.8	49

#	Article	IF	Citations
37	Acute Myelogenous Leukemia with t(8;21)â€"Identification of a Specific Immunophenotype. Leukemia and Lymphoma, 2003, 44, 1713-1718.	1.3	46
38	Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. British Journal of Haematology, 2004, 127, 311-321.	2.5	46
39	Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expression and Purification, 2004, 33, 123-133.	1.3	46
40	Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leukemia and Lymphoma, 2011, 52, 34-41.	1.3	45
41	Promyelocytic blast crisis in chronic granulocytic leukemia with 15;17 translocation. Leukemia Research, 1984, 8, 1019-1023.	0.8	44
42	The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cellsin vitro andin vivo. International Journal of Cancer, 1994, 56, 236-243.	5.1	44
43	Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007, 13, 925-931.	2.0	44
44	Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood, 2010, 116, 4859-4869.	1.4	40
45	Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.. Clinical Cancer Research, 2006, 12, 1284-1291.	7.0	39
46	AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin. PLoS ONE, 2013, 8, e53518.	2.5	39
47	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 341-348.	0.4	39
48	Nonclonal hemopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. American Journal of Hematology, 1987, 24, 389-394.	4.1	38
49	Detection of clonal karyotypic abnormalities in most patients with acute nonlymphocytic leukemia examined using short-term culture techniques. Cancer Genetics and Cytogenetics, 1986, 22, 239-251.	1.0	35
50	Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples. Analytical Chemistry, 2016, 88, 5680-5688.	6.5	35
51	Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genetics and Cytogenetics, 2006, 170, 16-23.	1.0	32
52	Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Experimental Hematology, 2009, 37, 450-460.	0.4	32
53	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350) Tj ETQq1 1 0.784314 rgBT /Overlo	2.0	32
54	Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biology of Blood and Marrow Transplantation, 2002, 8, 435-443.	2.0	30

#	Article	IF	Citations
55	Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 639-646.	2.0	30
56	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Experimental Hematology, 2015, 43, 858-868.e7.	0.4	28
57	Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma*. British Journal of Haematology, 2006, 133, 634-637.	2.5	27
58	Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leukemia Research, 2010, 34, 1358-1365.	0.8	27
59	Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood, 2003, 102, 3743-3752.	1.4	26
60	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. Blood, 2018, 132, 563-563.	1.4	26
61	Juvenile monosomy 7 syndrome: evidence that the disease originates in a pluripotent hemopoietic stem cell. Leukemia Research, 1987, 11, 705-709.	0.8	25
62	The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leukemia Research, 2004, 28, 1221-1226.	0.8	25
63	Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors. Biology of Blood and Marrow Transplantation, 2015, 21, 1437-1444.	2.0	24
64	IPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 205-213.	2.0	23
65	Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation. Blood, 2012, 119, 3431-3439.	1.4	23
66	Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20â€year cohort. British Journal of Haematology, 2012, 158, 174-185.	2.5	23
67	Single-Nucleotide Polymorphisms in Aldo-Keto and Carbonyl Reductase Genes Are Not Associated with Acute Cardiotoxicity after Daunorubicin Chemotherapy. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2118-2120.	2.5	22
68	Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by Flow Cytometry Is Associated With NPM1 and FLT3 Mutation Status in Cytogenetically Normal Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 274-279.	0.4	20
69	Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leukemia and Lymphoma, 2012, 53, 1321-1326.	1.3	19
70	Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice. Experimental Hematology, 1999, 27, 1609-1620.	0.4	18
71	Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Modern Pathology, 2004, 17, 1211-1216.	5.5	17
72	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1543-1551.	1.3	16

#	Article	IF	Citations
73	An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. Cancer Research, 2016, 76, 1214-1224.	0.9	16
74	Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Experimental Hematology, 2002, 30, 1316-1323.	0.4	15
75	Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2006, 12, 480-489.	2.0	15
76	A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leukemia Research, 2010, 34, 1035-1042.	0.8	15
77	Excellent realâ€world outcomes of adults with Burkitt lymphoma treated with <scp>CODOX</scp>â€M/<scp>IVAC</scp> plus or minus rituximab. British Journal of Haematology, 2018, 181, 782-790.	2.5	15
78	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 631-640.	1.3	15
79	Phase <scp>II</scp> study of targeted therapy with temozolomide in acute myeloid leukaemia and highâ€risk myelodysplastic syndrome patients preâ€screened for low O⁶â€methylguanine DNA methyltransferase expression. British Journal of Haematology, 2014, 167, 664-670.	2.5	14
80	Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience. Biology of Blood and Marrow Transplantation, 2018, 24, 1209-1215.	2.0	14
81	Flow cytometryâ€based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2012, 82B, 283-294.	1.5	13
82	Deep profiling of multitube flow cytometry data. Bioinformatics, 2015, 31, 1623-1631.	4.1	13
83	Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 784-790.	0.4	13
84	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Advances, 2021, 5, 1719-1728.	5.2	13
85	Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G-CSF. British Journal of Haematology, 1997, 99, 394-402.	2.5	12
86	Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies. BMC Genomics, 2013, 14, 550.	2.8	12
87	Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leukemia Research, 2012, 36, 900-904.	0.8	11
88	Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110Î´ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors. Leukemia Research, 2013, 37, 697-704.	0.8	11
89	Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e481-e491.	0.4	11
90	3 Cytokines acting early in human haematopoiesis. Best Practice and Research: Clinical Haematology, 1994, 7, 49-63.	1.1	10

#	Article	IF	Citations
91	Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Experimental Hematology, 2002, 30, 721-728.	0.4	10
92	Economic impact of genomic diagnostics for intermediateâ€risk acute myeloid leukaemia. British Journal of Haematology, 2016, 174, 526-535.	2.5	10
93	Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60â€“75. Blood, 2010, 116, 655-655.	1.4	10
94	SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. Blood, 2012, 120, 3625-3625.	1.4	10
95	Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.. Blood, 2010, 116, 3465-3465.	1.4	10
96	Cryopreserved mobilized autologous blood progenitors stored for more than 2 years successfully support blood count recovery after high-dose chemotherapy. Cytotherapy, 2011, 13, 856-863.	0.7	9
97	Continuous activation of primitive hematopoietic cells in long-term human marrow cultures containing irradiated tumor cells. Journal of Cellular Physiology, 1991, 148, 370-379.	4.1	8
98	Cytogenetics and oncogenes in leukemia. Current Opinion in Oncology, 1994, 6, 3-13.	2.4	7
99	Characterization of variant diphtheria toxinâ€“interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials. Biologicals, 2010, 38, 144-149.	1.4	7
100	Selective small molecule inhibitors of p110Î± and Î´ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors. Experimental Hematology, 2012, 40, 922-933.	0.4	7
101	Expression of Integrin Î±2 Receptor in Human Cord Blood CD34+CD38â^'CD90+ Stem Cells Engrafting Long-Term in NOD/SCID-IL2RÎ³cnull Mice. Stem Cells, 2013, 31, 360-371.	3.2	7
102	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2013, 122, 2682-2682.	1.4	7
103	Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function. Leukemia Research, 2015, 39, 689-695.	0.8	6
104	Health state utilities associated with treatment options for acute myeloid leukemia (AML). Journal of Medical Economics, 2019, 22, 567-576.	2.1	6
105	Allografting in chronic myeloid leukemia with cultured marrow: Update of the vancouver study. Stem Cells, 1993, 11, 64-66.	3.2	5
106	Immunotherapy of Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology, 2001, 2, 209-215.	1.6	5
107	Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2017, 58, 909-915.	1.3	5
108	Single-Nucleotide Polymorphisms in Reductase Genes Are not Associated with Response to Daunorubicin-Based Remission Induction. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1918-1920.	2.5	4

#	Article	IF	Citations
109	Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia and Lymphoma, 2005, 46, 525-531.	1.3	3
110	Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.. Blood, 2009, 114, 2071-2071.	1.4	3
111	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood, 2010, 116, 3298-3298.	1.4	3
112	Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy. Blood, 2012, 120, 1372-1372.	1.4	3
113	CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors. Blood, 2012, 120, 3626-3626.	1.4	3
114	Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, 7036-7036.	1.6	3
115	Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.. Blood, 2004, 104, 900-900.	1.4	2
116	Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia. Blood, 2010, 116, 501-501.	1.4	2
117	Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada. EJHaem, 2020, 1, 69-78.	1.0	1
118	High Risk AML Outpatient Management: A Retrospective Analysis of Bacteremia Incidence Following Chemotherapy.. Blood, 2004, 104, 884-884.	1.4	1
119	Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leukemia Research, 2009, 33, 1149-1150.	0.8	0
120	Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e427-e436.	0.4	0
121	Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2004, 104, 3325-3325.	1.4	0
122	Daclizumab Therapy Improves Outcome in Steroid Refractory Acute Graft Versus Host Disease (aGVHD).. Blood, 2004, 104, 5092-5092.	1.4	0
123	Septicemia in Chemotherapy Induced Neutropenic Acute Myeloid Leukemia (AML) Inpatients and Outpatients: A 5 Year Retrospective Experience.. Blood, 2004, 104, 4525-4525.	1.4	0
124	Risk Stratification in Acute Promyelocytic Leukemia Based on Elevated White Cell Count and Reduced Platelet Count Does Not Identify Subsequent Relapses: A Retrospective Review of 60 Patients.. Blood, 2004, 104, 4522-4522.	1.4	0
125	Long-Term Follow-Up Results of Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL)-The Vancouver Experience.. Blood, 2005, 106, 4578-4578.	1.4	0
126	Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.. Blood, 2005, 106, 1120-1120.	1.4	0

#	Article	IF	Citations
127	Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Blood, 2008, 112, 3305-3305.	1.4	0
128	Distinct Signaling Profiles of Gemtuzumab Ozogamicin Responsiveness and Refractoriness in Acute Myeloid Leukemia.. Blood, 2009, 114, 2745-2745.	1.4	0
129	Short Progression Free Survival Post Non-Myeloablative Sibling Allogeneic Stem Cell Transplantion for Multiple Myeloma.. Blood, 2009, 114, 4323-4323.	1.4	0
130	Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia.. Blood, 2009, 114, 2960-2960.	1.4	0
131	Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months).. Blood, 2009, 114, 2872-2872.	1.4	0
132	Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease. Blood, 2010, 116, 353-353.	1.4	0
133	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	1.4	0
134	Selective Small Molecule Inhibition of P110Î± and Î´ Isoforms of PI3 Kinase Is Cytotoxic to Human AML Progenitors. Blood, 2011, 118, 1556-1556.	1.4	0
135	Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia. Blood, 2016, 128, 5852-5852.	1.4	0